Annonce

Log ud Log ind
Log ud Log ind
Formue

AstraZeneca genstarter Fase III forsøg med COVID-19

Morten W. Langer

lørdag 12. september 2020 kl. 19:06

Fra Zerohedge:

AstraZeneca announced on Saturday that its Phase 3 COVID-19 study would resume, days after a participant fell ill.

The company said in a statement that “the standard review process had triggered a voluntary pause,” to all global trials on September 6, and that the Medicines Health Regulatory Authority had given the green light to resume the trials conducted through the University of Oxford after reviewing the safety data.

The company says that it will “continue to work with health authorities across the world and be guided as to when other clinical trials can resume to provide the vaccine broadly, equitably and at no profit during this pandemic.”

At least 18,000 people have received the experimental treatment as part of the trial.

Earlier this week, AstraZeneca CEO Pascal Soriot said during a private conference call  that the “potentially unexplained illness” occurred in a UK woman who displayed neurological symptoms consistent with transverse myelitis – a spinal inflammatory disorder, according to STAT News. Soriot also confirmed that the company’s clinical research trials had been halted in July after a different participant experienced neurological symptoms which were found to be unrelated to the experimental vaccine.

“In large trials such as this, it is expected that some participants will become unwell and every case must be carefully evaluated to ensure careful assessment of safety,” reads a statement from Oxford.

AstraZeneca’s potential coronavirus vaccine, called AZD1222, is among the frontrunners in the race toward a safe and effective vaccine that could put a dent in the global pandemic. The company launched its late-stage trials at the end of August. It’s one of at least three vaccine candidates, along with Pfizer’s and Moderna’s, in late-stage trials.

Officials from the World Health Organization have previous hailed AstraZeneca’s vaccine candidate as one of the most promising currently in development. On Thursday, WHO Chief Scientist Dr. Soumya Swaminathan said there’s no need to be “overly discouraged” by the news of the pause of the trial, adding that “these things happen.” –CNBC

“I think this is a good … perhaps a wake-up call or a lesson for everyone to recognize the fact that there are ups and downs in research, there are ups and downs in clinical development and we have to be prepared for those,” said WHO’s Chief Scientist.

Meanwhile, Pfizer/BioNTech announced on Saturday that their Phase 3 COVID-19 trial would increase from 30,000 participants to 44,000 – which will ‘allow for the enrollment of new populations,’ by including ‘adolescents as young as 16 years of age and people with chronic, stable HIV, Hepatitis C or Hepatitis B.’

Tilmeld dig vores gratis nyhedsbrev
ØU Top100 Finansvirksomhed

Få de vigtigste om bank, realkredit, forsikring, pension
Udkommer hver mandag.

Jeg giver samtykke til, at I sender mig mails med de seneste historier fra Økonomisk Ugebrev. Lejlighedsvis må I gerne sende mig gode tilbud og information om events. Samtidig accepterer jeg ØU’s Privatlivspolitik.

Du kan til enhver tid afmelde dig med et enkelt klik.

[postviewcount]

Jobannoncer

Grønborg: Bankernes rejse nærmer sig afslutningen
Forretningsudvikler til Pension og Formue
Pension, Formue
Aabenraa
Grønborg: Bankernes rejse nærmer sig afslutningen
Formuerådgiver
Formuerådgiver
Midt- og Nordjylland
Grønborg: Bankernes rejse nærmer sig afslutningen
Afdelingsdirektør for forretningsudvikling Private Banking
Private Banking
Aabenraa
Grønborg: Bankernes rejse nærmer sig afslutningen
Formuerådgiver
Formuerådgiver
Region hovedstaden og Sjælland
Generalsekretær i Folkekirkens Nødhjælp
Region Hovedstaden
ØKONOMIMEDARBEJDER – Carlsbergfondet
Region Hovedstaden
Regnskabsassistent til Pharma Nord
Region Syddanmark
Kontorchef for økonomi, analyse og kunder i Færdselsstyrelsen
Region H
DIGITALISERINGSCHEF – Muskelsvindfonden
Region H
Direktionskonsulent med flair for økonomi og udviklingsprojekter
Region Sjælland

Mere fra ØU Formue

Log ind

Har du ikke allerede en bruger? Opret dig her.

FÅ VORES STORE NYTÅRSUDGAVE AF FORMUE

Her er de 10 bedste aktier i 2022

Tilbuddet udløber om:
dage
timer
min.
sek.

Analyse af og prognoser for Fixed Income (statsrenter og realkreditrenter)

Direkte adgang til opdaterede analyser fra toneangivende finanshuse:

Goldman Sachs

Fidelity

Danske Bank

Morgan Stanley

ABN Amro

Jyske Bank

UBS

SEB

Natixis

Handelsbanken

Merril Lynch 

Direkte adgang til realkreditinstitutternes renteprognoser:

Nykredit

Realkredit Danmark

Nordea

Analyse og prognoser for kort rente, samt for centralbankernes politikker

Links:

RBC

Capital Economics

Yardeni – Central Bank Balance Sheet 

Investing.com: FED Watch Monitor Tool

Nordea

Scotiabank